Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg

• Ngā kaituhi matua: Klervi Golhen (Author), Michael Buettcher (Author), Jörg Huwyler (Author), John van den Anker (Author), Verena Gotta (Author), Kim Dao (Author), Laura E. Rothuizen (Author), Kevin Kobylinski (Author), Marc Pfister (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2024-09-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

The antiparasitic drug ivermectin is approved for persons > 15 kg in the US and EU. A pharmacometric (PMX) population model with clinical PK data was developed (i) to characterize the effect of the patient-friendly ivermectin formulation CHILD-IVITAB on the absorption process and (ii) to evaluate...